They're all talking about HPV, or human papillomavirus. It's the most common sexually transmitted infection, but it's also ...

Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.

Merck’s MRK fourth-quarter revenue grew 7% to $15.6 billion (including Keytruda growth of 21% to $7.8 billion), in line with ...

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...

Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant headwinds going into 2025.

Merck's stock tumbled 11.8% Tuesday, putting it on track for its biggest one-day selloff in almost 17 years, after the drug company's softer-than-expected guidance amid struggles for its HPV vaccine ...

The drugmaker’s guidance was affected by a pause in shipments of its top-selling vaccine to China from February through at ...

Merck blamed the lower than expected forecast on the decision to pause shipments of its Gardasil vaccine to China until at least mid-year. Gardasil is given to patients to prevent human papillomavirus ...

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

Robert F. Kennedy Jr. has cleared his first hurdle to become the nation’s top health official as the Senate finance committee ...

With a committee vote scheduled Tuesday for Robert F. Kennedy Jr.'s confirmation to lead the Department of Health and Human Services, Senate Democrats are demanding more details on the nominee's ...

Facing intense scrutiny from senators over his potential profit from vaccine lawsuits while serving as the nation’s health ...